BCAX (Bicara Therapeutics) EBITDA Margin % : 0.00% (As of Dec. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Bicara Therapeutics EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Bicara Therapeutics's EBITDA for the three months ended in Dec. 2024 was $-26.62 Mil. Bicara Therapeutics's Revenue for the three months ended in Dec. 2024 was $0.00 Mil. Therefore, Bicara Therapeutics's EBITDA margin for the quarter that ended in Dec. 2024 was 0.00%.

Bicara Therapeutics EBITDA Margin % Historical Data

The historical data trend for Bicara Therapeutics's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bicara Therapeutics EBITDA Margin % Chart

Bicara Therapeutics Annual Data

Trend

Dec22

Dec23

Dec24

EBITDA Margin %

Bicara Therapeutics Quarterly Data
	Dec22	Sep23	Dec23	Jun24	Sep24	Dec24
EBITDA Margin %	Get a 7-Day Free Trial			-	-	-	-	-

Competitive Comparison of Bicara Therapeutics's EBITDA Margin %

For the Biotechnology subindustry, Bicara Therapeutics's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Bicara Therapeutics's EBITDA Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Bicara Therapeutics's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Bicara Therapeutics's EBITDA Margin % falls into.

Save Embed

;

Save Embed

;

Bicara Therapeutics EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Bicara Therapeutics's EBITDA Margin % for the fiscal year that ended in Dec. 2024 is calculated as

EBITDA Margin %	=	EBITDA (A: Dec. 2024 )	/	Revenue (A: Dec. 2024 )
	=	-82.333	/	0
	=	%

Bicara Therapeutics's EBITDA Margin % for the quarter that ended in Dec. 2024 is calculated as

EBITDA Margin %	=	EBITDA (Q: Dec. 2024 )	/	Revenue (Q: Dec. 2024 )
	=	-26.622	/	0
	=	%

Bicara Therapeutics (NAS:BCAX) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Bicara Therapeutics EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Bicara Therapeutics's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Bicara Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bicara Therapeutics Inc (NAS:BCAX) » Definitions » EBITDA Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

116 Huntington Avenue, Suite 703, Boston, MA, USA, 02116

Website

Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b.